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ABSTRACT
Objectives To explore whether, in early fetal growth
restriction (FGR), the longitudinal pattern of fetal heart
rate (FHR) short-term variation (STV) can be used to
identify imminent fetal distress and whether abnormalities
of FHR recordings are associated with 2-year infant
outcome.
Methods The original TRUFFLE study assessed whether,
in early FGR, delivery based on ductus venosus (DV)
Doppler pulsatility index (PI), in combination with
safety-net criteria of very low STV on cardiotocography
(CTG) and/or recurrent FHR decelerations, could
improve 2-year infant survival without neurological
impairment in comparison with delivery based on CTG
monitoring only. This was a secondary analysis of women
who delivered before 32 weeks and had consecutive
STV data recorded > 3 days before delivery and known
infant outcome at 2 years of age. Women who received
corticosteroids within 3 days of delivery were excluded.
Individual regression line algorithms of all STV values,
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except the last one before delivery, were calculated. Life
tables and Cox regression analysis were used to calculate
the daily risk for low STV or very low STV and/or FHR
decelerations (below DV group safety-net criteria) and to
assess which parameters were associated with this risk.
Furthermore, it was assessed whether STV pattern, last
STV value or recurrent FHR decelerations were associated
with 2-year infant outcome.
Results One hundred and forty-nine women from the
original TRUFFLE study met the inclusion criteria. Using
the individual STV regression lines, prediction of a last
STV below the cut-off used by the CTG monitoring
group had sensitivity of 42% and specificity of 91%.
For each day after study inclusion, the median risk for
low STV (CTG group cut-off) was 4% (interquartile
range (IQR), 2–7%) and for very low STV and/or
recurrent FHR decelerations (below DV group safety-net
criteria) was 5% (IQR, 4–7%). Measures of STV pattern,
fetal Doppler (arterial or venous), birth-weight multiples
of the median and gestational age did not usefully
improve daily risk prediction. There was no association
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of STV regression coefficients, a low last STV and/or
recurrent FHR decelerations with short- or long-term
infant outcomes.
Conclusion The TRUFFLE study showed that a strategy
of DVmonitoring with safety-net criteria of very low STV
and/or recurrent FHR decelerations for delivery indication
could increase 2-year infant survival without neurological
impairment. This post-hoc analysis demonstrates that, in
early FGR, the daily risk of abnormal CTG, as defined
by the DV group safety-net criteria, is 5%, and that
prediction is not possible. This supports the rationale for
CTG monitoring more often than daily in these high-risk
fetuses. Low STV and/or recurrent FHR decelerations
were not associated with adverse infant outcome and it
appears safe to delay intervention until such abnormalities
occur, as long as DV-PI is within normal range. Copyright
 2016 ISUOG. Published by John Wiley & Sons Ltd.
INTRODUCTION
Fetal growth restriction (FGR) in the early preterm period
is associated with significant risks of perinatal mortality
and neonatal morbidity. The most important prognostic
factors are gestational age at delivery and birth weight.
The main challenge in management of FGR is the timing
of delivery, for which the risk of acidosis or fetal death has
to be weighed against the benefits of increasing gestational
age. Typically, fetuses are not delivered until it is certain
that they no longer benefit from a prolonged intrauterine
stay. Prior to the development of terminal acidosis
and absence of fetal movement, a gradual decrease in
fetal heart rate (FHR) short-term variation (STV), FHR
deceleration and gradual decrease in fetal movement have
been described1,2. If there was a process in place so that
these could be identified in a timely manner, the additive
risks of acidosis could potentially be avoided, without
compromising the benefits of increasing gestational
age.
The recently published Trial of Umbilical and Fetal
Flow in Europe (TRUFFLE) study was designed to
investigate in pregnancies complicated by early FGR
whether fetal monitoring of ductus venosus (DV)
pulsatility index (PI), in combination with STV on
computerized cardiotocography (CTG), could improve
long-term infant outcome in comparison with monitoring
by CTG only3. Women with FGR between 26+0 and
31+6weeks were randomized to three different strategies
for delivery intervention (DV-PI > 95th percentile, absent
A-wave in the DV or low CTG only). The study
concluded that monitoring of DV-PI, in combination with
safety-net criteria of very low STV and/or recurrent FHR
decelerations, could reduce the risk of infant neurological
impairment at 2 years in comparison with monitoring by
CTG only.
This secondary analysis of data from the TRUFFLE
study was intended to explore, in a group of fetuses
with early FGR, the longitudinal pattern of STV
recordings, the rate at which STV decreased below
the intervention cut-off and whether an association
exists between longitudinal STV pattern or STV below
intervention cut-off and perinatal parameters and 2-year
infant outcome.
METHODS
The TRUFFLE study design has been described
previously3. Briefly, women with a singleton preg-
nancy between 26+0 and 31+6weeks of gesta-
tion with fetal abdominal circumference < 10th per-
centile and umbilical artery Doppler PI > 95th per-
centile were included in a 20-center European study
(ISRCTN, 56204499). Women were allocated at ran-
dom to one of three monitoring strategies for deliv-
ery: (1) reduced STV (< 3.5 ms before 29 weeks and
< 4.0 ms thereafter) on CTG, (2) early DV Doppler
changes (DV-PI > 95th percentile – ‘DV-p95’ group)
and (3) late DV Doppler changes (A-wave at or below
baseline – ‘DV-no-A’ group). Abnormal DV-PI measure-
ments were to be repeated within 24 h, if CTG results
allowed this, to demonstrate consistency. In all groups, the
timing of delivery could also be decided by safety-net cri-
teria if the CTG showed recurrent decelerations in FHR or
when STV in the DV groups was very low (STV <2.6ms
before 29 weeks and < 3.0 ms thereafter). The Oxford
Sonicaid 8002 system or an equivalent Dawes–Redman
software-based algorithm was used for STV calculation4.
Recordings were at least 45 min in duration. Most partic-
ipating centers (17/20) performed CTG at least daily. The
remaining centers performed CTG on alternate days, but
more often on indication.
For birth weight, multiples of the median (MoM) were
calculated. The 50th weight percentile from a fetal growth
chart, adjusted for gestational age, maternal ethnicity,
weight, height and neonatal sex, was used as normalized
median fetal weight5.
The primary TRUFFLE study outcome was infant
survival at 2 years of age with normal neurological
development (adjusted for prematurity), defined by a
score > 85 on the Bayley Scales of Infant and Toddler
Development (third edition) (PsychCorp, San Antonio,
TX, USA) and absence of severe vision or hearing
deficiency or cerebral palsy3. A secondary outcome was
severe neonatal morbidity, defined as bronchopulmonary
dysplasia (need for additional oxygen at 36 weeks
adjusted age), germinal matrix hemorrhage Grade 3 or
4, periventricular leukomalacia >Grade 1, necrotizing
enterocolitis (confirmed by X-ray or laparotomy) or
microbiologically proven sepsis.
This secondary analysis included all women who had
been included in the study for > 3 days before delivery,
had at least four CTG recordings in the last week
before delivery and at least one CTG recording in
the last 24 h before delivery and were delivered before
32weeks. This last inclusion criterion was necessary
because, after 32 weeks, protocol-driven monitoring was
no longer followed and therefore STVmeasurements were
no longer entered consistently into the study database.
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Women who received corticosteroids within 3 days before
delivery were excluded as it has been observed that STV
increases shortly after corticosteroid administration and
decreases on day 2–3 after administration6,7. Because
a more prolonged effect of corticosteroids could not be
excluded, we analyzed monitoring data separately for
women who delivered within 1 week after corticosteroid
administration and women who delivered later or did
not receive corticosteroids. The TRUFFLE study was
approved by the ethics committees of all participating
units.
For overview of STV data, a boxplot was created using
STV values recorded in the last 3 weeks before delivery,
grouped into time periods of 3-, 2- or 1-day intervals. If
women had more than one STV measurement in a time
period, only the last measurement was selected.
Individual longitudinal STV analysis was performed
by linear and by exponential regression analyses, with
or without adjustment for a last STV above or below
the CTG group cut-off or for primary infant outcome.
Goodness of fit was calculated by the average squared
difference of observed and expected STV. Because linear
and exponential regression did not differ in this respect
and adjustments did not improve the fit (data not shown),
we decided to use only linear regression for individual
data analysis.
Linear regression analysis was performed for each
woman using all STV data except the last measurement
before delivery. Based on the differences between observed
and expected STV values, the SD from the regression
line could be calculated for each woman. This allowed
assessment of whether the last STV measurement (which
was exempted from this regression line calculation) was
in line with earlier measurements or diverted > 2 SD
from the expected STV value. Figure 1 demonstrates this
method for two women, one with last STV value > 2 SD
below the previous values and one with last (but low)
value in line with expectations, based on the regression
line of earlier STV values.
For each woman, an expected last STV (STVexpected)
could be calculated using the individual regression
algorithm based on all STV values except the last one.
Sensitivity and specificity of STVexpected for prediction of
STV below the CTG group cut-off were calculated.
Life table analysis was used to calculate the daily risk
of low STV below the CTG group cut-off and of very
low STV and/or recurrent FHR decelerations (DV group
safety-net criteria). Using Cox regression analysis, it was
assessed if the daily risk could be better predicted by
the individual regression line slope angle, randomization
group allocation, ratio of umbilical artery PI to fetal
middle cerebral artery PI (U/C ratio), absent or reversed
end-diastolic velocity in the umbilical artery (ARED flow),
gestational age and birth-weight MoM. Birth weight was
used as it should be similar to fetal weight during the last
week of pregnancy in FGR and is more precise than fetal
weight calculated by ultrasound biometry. Odds ratios
(ORs) were calculated with 95% CI. Estimation of the
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Figure 1 Examples of acute (a) and gradual (b) change in fetal
heart rate short-term variation (STV) in two individual pregnancies
to a value below the cardiotocography group cut-off for indication
for delivery. Linear regression line ± 2 SD is shown for all STV
values in last week before delivery, excluding last STV value before
delivery. Last STV measurement is below 2 SD in (a) and within 2
SD in (b).
area under the receiver–operating characteristics curve
(AUC) was used to assess the efficacy of a model.
Based on the regression coefficient of a linear model of
all STV recordings of the study population during the last
3 weeks before delivery, a regression coefficient < –0.1 (a
decrease of 1 ms per 10 days or negative slope angle >6◦)
was defined as a decreasing STV pattern. If the regression
coefficient was ≥ –0.1 or the angle of the regression line
was < 6◦, the STV pattern was defined as stable.
Perinatal and outcome data were compared between
women with and those without a decreasing STV regres-
sion line and women with a last STV value within the
expected range and those with STVmore than 2 SD below
the expected value. By combining these two classifications,
we could define four groups for comparison.
ORs of 2-year infant survival without neurological
impairment were calculated for a decreasing STV
regression line, a last STV below the CTG group criteria,
a last STV below the DV group safety-net criteria and last
Copyright  2016 ISUOG. Published by John Wiley & Sons Ltd. Ultrasound Obstet Gynecol 2017; 50: 71–78.
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STV with recurrent FHR decelerations, with adjustment
for birth-weight MoM and gestational age.
Homogeneity of data was tested by Levene statistics
to decide between parametric and non-parametric testing.
Groups were compared by ANOVA, Kruskal–Wallis,
Mann–Whitney U, Pearson’s chi-square or Fisher’s exact
test, as appropriate. Multivariable analysis was performed
by a backwards stepwise procedure with P< 0.1 to
exclude potential variables from the model. Statistical
analyses were performed with SPSS Statistics version 23
(IBM Corp., Armonk, NY, USA).
RESULTS
One hundred and forty-nine (42%) women of the 356
women who delivered before 32 weeks qualified for
inclusion in this secondary analysis (Table 1). The main
reason for exclusion (41%) was delivery or fetal death
within 3 days after study inclusion. Eight women who
complied with the CTG frequency inclusion criteria were
excluded from longitudinal analysis because they had
received corticosteroids within 3 days before delivery.
In five of these, a second course of corticosteroids had
Table 1 Selection of women for analysis by stepwise application of
inclusion criteria to TRUFFLE study population of 356 women
who delivered < 32 weeks’ gestation
Inclusion criterion n (%)
Two-year infant follow-up (or known death) 322 (90)
Delivered or fetal death >3 days after study inclusion 175 (49)
Sufficient cardiotocography data for analysis 157 (44)
Corticosteroids administered > 3 days before delivery
or not received
149 (42)
been given shortly before delivery (including one with
unexpected fetal death) and the other three had received
corticosteroids 1–5 days after randomization. Table 2
shows perinatal data of the study population, grouped
according to the time interval from administration of
corticosteroids to delivery. This table includes data on
the eight women with a short corticosteroid-to-delivery
interval whowere excluded from the longitudinal analysis.
Median gestational age at delivery was 30 weeks, mean
birth weight was 880 g and birth-weight MoM was 0.57.
Fetal death occurred in two (1%) cases (Table 2),
of which one was excluded from longitudinal analysis
because of a short corticosteroid-to-delivery interval. In
both cases, the last CTG performed approximately 12 h
before fetal death was normal (mean STV, 5ms), but
one case had a DV-PI >95th percentile (randomized
to DV-no-A group). The additional fetal deaths in the
TRUFFLE study (n= 10) were not included in the analysis
because the number of CTG recordings was insufficient
for longitudinal analysis. In one case, a borderline
STV (2.7ms) was recorded approximately 12 h before
fetal death. Two cases had normal STV (mean, 5.7ms)
approximately 24 h before fetal death, one of which had a
DV-PI>95th percentile. Twowomen refused intervention
when indicated for delivery by low STV and recurrent
FHR decelerations and fetal death was confirmed 24 h
later. In five fetal deaths, the interval between the last
CTG and fetal death was more than 24 h. Three of
these had refused further monitoring and intervention.
Neonatal mortality occurred in 6% and severe neonatal
morbidity in 29% of the infants. Eighty-two percent of
infants were classified as normal at the corrected age of
2 years.
Table 2 Longitudinal fetal heart rate (FHR) short-term variation (STV) patterns and perinatal outcome in 157 pregnancies with fetal growth
restriction, according to timing of corticosteroid administration
Interval between corticosteroid administration and delivery
Parameter ≤ 3days (n = 8) 4–7 days (n = 23) >7days (n = 126)† All (n = 157)
Randomized to CTG monitoring group 2 (25) 9 (39) 38 (30) 49 (31)
STV regression coefficient < –0.3 (decrease) — 12 (52)* 12 (10) 24 (15)
STV regression coefficient < –0.1 (decrease) — 17 (74)* 44 (35) 61 (39)
Last STV before delivery > 2 SD below earlier recordings — 8 (35) 53 (42) 61 (39)
Last STV below CTG group cut-off 3 (38) 16 (70)* 46 (37) 65 (41)
Last STV below DV group safety-net criteria‡ 3 (38) 14 (61) 61 (48) 78 (50)
Umbilical artery ARED flow 4 (50) 13 (57) 56 (44) 73 (46)
U/C ratio 1.4 ± 0.38 1.7 ± 0.7 1.5 ± 0.5 1.5 ± 0.5
Days from randomization to delivery 12 (7–15) 5 (5–6)* 11 (8–17) 11 (7–16)
Fetal death 1 (13) 0 (0) 1 (1) 2 (1)
Gestational age at delivery (weeks) 30.9 (29.2–31.5) 29.0 (28.3–30.4)* 30.1 (29.0–31.0) 30.0 (28.9–30.9)
Birth weight (g) 927 ± 239 836 ± 218 884 ± 194 880 ± 200
Birth-weight MoM 0.56 ± 0.07 0.56 ± 0.09 0.57 ± 0.09 0.57 ± 0.09
Severe neonatal morbidity 2 (25) 9 (39) 34 (27) 45 (29)
Neonatal mortality 1 (13) 3 (13) 6 (5) 10 (6)
Normal 2-year infant outcome 6 (75) 15 (65) 108 (86) 129 (82)
Data are given as n (%), mean ± SD or median (range). Comparison of women with corticosteroids 4–7 days vs > 7 days before delivery by
Fisher’s exact test or Mann–Whitney U-test: *P < 0.05. †Five women in this group did not receive corticosteroids. ‡Very low STV and/or
FHR decelerations. ARED, absent or reversed end-diastolic; CTG, cardiotocography; DV, ductus venosus; MoM, multiples of the median;
U/C ratio, umbilical artery pulsatility index to fetal middle cerebral artery pulsatility index ratio.
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Figure 2 Boxplot of fetal heart rate short-term variation (STV)
measurements in all women in study group (n = 149), according to
length of time before delivery or fetal death. Median, interquartile
range, range and outliers are shown.
Figure 2 shows a boxplot of STV recordings, grouped
according to the time period at which the measurement
was taken in the last 3 weeks before delivery. A linear
model of all STV recordings showed a slow decrease
in STV values (algorithm: 5.36 – 0.11 × (days before
delivery); 95%CI, ± 4ms). Other models (quadratic,
cubic, logistic) gave residuals identical to or higher than
those of the linear model. As can be seen in Figure 2, the
most prominent decrease in STV was on the day before
delivery. The last STV measurements before delivery were
significantly lower than earlier measurements. Repeating
the linear regression of STV recordings, excluding those
obtained on the day before delivery, showed a stable,
nearly horizontal pattern (algorithm: 5.71 – 0.04 × (days
before delivery) or a decrease of 1 ms/25 days).
A linear decrease in the individual STV regression line
with a regression coefficient <–0.1 (or a slope angle
<–6o) occurred in 61 (41%) women and a regression
coefficient <–0.3 (or a slope angle <–17o) was observed
in only 24 (16%) of these. Using all STV data of the 88
women with a regression coefficient ≥–0.1 gave a median
Table 3 Perinatal data of 149 pregnancies with fetal growth restriction, according to last fetal heart rate (FHR) short-term variation (STV)
value before delivery within 2 SD (last STV ± 2 SD) or more than 2 SD below (last STV <2 SD) all previous STV values, and STV regression
coefficient ≥ –0.1 (or slope angle ≥ –6◦, stable) or < –0.1 (decreasing) for all STV recordings except last STV
Regression line classification
Stable STV Decreasing STV
Parameter Last STV ± 2 SD Last STV < 2 SD Last STV ± 2 SD Last STV <2 SD All
n (%) 40 (27) 48 (32) 48 (32) 13 (9) 149 (100)
At inclusion
Gestational age (weeks) 28.0 (26.9–29.0) 28.1 (27.2–29.4) 28.1 (27.0–29.4) 28.1 (27.0–29.4) 28.1 (27.0–29.3)
Randomization to CTG group 14 (35) 17 (35) 13 (27) 3 (23) 47 (32)
Estimated fetal weight (g)* 730 ± 134 791 ± 173 840 ± 180 774 ± 171 789 ± 170
Estimated fetal weight MoM* 0.61 ± 0.10 0.66 ± 0.09 0.67 ± 0.08 0.63 ± 0.07 0.65 ± 0.09
Corticosteroids 4–7 days before delivery* 2 (5) 4 (8) 13 (27) 4 (31) 23 (15)
After inclusion
Highest U/C ratio* 1.8 ± 0.9 1.8 ± 0.7 3.0 ± 1.8 2.7 ± 1.3 2.2 ± 1.2
Umbilical artery ARED flow 19 (48) 21 (44) 24 (50) 5 (38) 69 (46)
Last CTG
Recurrent FHR decelerations 21 (53) 21 (44) 20 (42) 4 (31) 66 (44)
STV <CTG group cut-off* 6 (15) 23 (48) 21 (44) 7 (54) 57 (38)
STV <DV group cut-off 1 (3) 5 (10) 8 (17) 3 (23) 17 (11)
STV <DV group safety-net criteria† 22 (55) 23 (48) 25 (52) 5 (38) 75 (50)
Gestational hypertension 27 (68) 38 (79) 42 (88) 12 (92) 119 (80)
Days from inclusion to delivery* 13 (9–17) 11 (6–17) 8 (5–11) 8 (6–17) 10 (7–16)
Fetal death 1 (3) 0 (0) 0 (0) 0 (0) 1 (1)
Liveborn (% of all liveborn) 39 (26) 48 (32) 48 (32) 13 (9) 148 (100)
Gestational age at delivery (weeks) 30.1 (29.6–30.9) 30.4 (28.9–31.0) 29.8 (28.5–30.9) 29.7 (28.6–31.2) 30.0 (28.8–30.9)
Birth weight (g) 834 ± 173 899 ± 206 892 ± 211 862 ± 196 877 ± 198
Birth-weight MoM* 0.53 ± 0.10 0.58 ± 0.09 0.59 ± 0.09 0.55 ± 0.08 0.57 ± 0.09
Male neonate 16 (40) 26 (54) 26 (54) 9 (69) 77 (52)
Umbilical artery pH < 7.0 (n = 124) 0 (0) 0 (0) 0 (0) 1 (8) 1 (1)
Severe neonatal morbidity‡ 13 (33) 10 (21) 14 (29) 6 (46) 43 (29)
Neonatal death 4 (10) 2 (4) 3 (6) 0 (0) 9 (6)
Neurological impairment at 2 years 6 (15) 3 (6) 4 (8) 3 (23) 16 (11)
Alive and normal at 2 years 29 (73) 43 (90) 41 (85) 10 (77) 123 (83)
Data are given as n (%), median (range) or mean ± SD. Groups compared by ANOVA or Pearson’s chi-square test: *P < 0.05. †Very low
STV and/or recurrent FHR decelerations. ‡Components include bronchopulmonary dysplasia (need for additional oxygen at 36 weeks
adjusted age), germinal matrix hemorrhage Grade 3 or 4, periventricular leukomalacia >Grade 1, necrotizing enterocolitis (confirmed by
X-ray or laparotomy) or microbiologically proven sepsis. ARED, absent or reversed end-diastolic; CTG, cardiotocography; DV, ductus
venosus; MoM, multiples of the median; U/C ratio, umbilical artery pulsatility index to fetal middle cerebral artery pulsatility index ratio.
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regression coefficient of –0.001, which can be interpreted
as horizontal.
Women who received corticosteroids 4–7 days before
delivery (n = 23; 15%) had both a regression coefficient
<–0.1 and a last STV below CTG group cut-off
approximately twice as often as women who received no
corticosteroids (n = 5) or had corticosteroids more than 7
days before delivery (n = 121) (Table 2; P < 0.05). There
was a statistically significant difference in the time interval
from inclusion to delivery between these two groups, but
there was no difference in Doppler parameters, gestational
age at delivery, birth weight or birth-weight MoM.
The study group was subdivided into four groups
based on the value of the individual STV regression line
coefficient being more or less than –0.1 (or slope angle
of –6◦) and the last STV being more or less than 2 SD
below the regression line calculated using all STV values
except the last measurement before delivery. There were
no differences between these groups for gestational age at
randomization, gestational age at delivery, birth weight,
severe neonatal morbidity or 2-year infant outcome
(Table 3). In the first group (stable STV pattern with
a last STV within 2 SD), estimated fetal weight and
birth-weight MoM were lower. Only six (15%) women
in this group had a low last STV and in these women
STV was just above the CTG group cut-off at inclusion.
In the other classification groups, a low last STV occurred
approximately three times more frequently. In those with
a decreasing STV pattern, U/C ratio was higher. Within
the classification groups, data were similar for women
who received corticosteroids 4–7 days before delivery in
comparison with the remaining women.
In 61 (41%) women, the last STV value was more than
2 SD below the individual regression line. In half of these
women (n = 30; 49%), the last STV value was below the
CTG group cut-off. In 88 (59%) women, the last STV
was within 2 SD of the regression line, and in 27 of these
(31%), the STV value was below the CTG group cut-off
(Table 3).
The sensitivity of STVexpected below the CTG-STV
group cut-off for prediction of a last STV lower than
the CTG group cut-off was 42% and specificity was
91%, with an OR of 2.5 (95% CI, 1.7–3.8). Combining
low STVexpected with randomization allocation, time of
corticosteroid administration of 4–7 days vs > 7days
before delivery, gestational age, birth weight and
fetal Doppler measurements (arterial or venous) in a
multivariable analysis did not improve prediction of low
STV below the CTG group cut-off.
Life table analysis showed that, for each day after
inclusion, the median risk for low STV below the CTG
group cut-off was 4% (interquartile range (IQR), 2–7%).
The daily risk for very low STV and/or recurrent FHR
decelerations (DV group safety-net criteria) was 5% (IQR,
4–7%). Stratification of the analysis for allocation to
DV or CTG monitoring groups did not show significant
differences between the allocation groups. Cox regression
analysis demonstrated that only addition of the STV
regression coefficient and a last STVexpected improved
0.50
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safety-net
STV below CTG
group cut-off
Recurrent
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Regression line
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Figure 3 Odds ratios with 95% CIs for 2-year infant survival
without neurological impairment for a longitudinal decrease in
fetal heart rate (FHR) short-term variation (STV) (regression line
coefficient), recurrent FHR decelerations and last STV before
delivery below cardiotocography (CTG) group cut-off and below
ductus venosus (DV) group safety-net criteria cut-off for indication
of delivery. Odds ratios were calculated separately with adjustment
for gestational age at delivery and birth-weight multiples of the
median.
slightly the risk estimate for a low STV below the
CTG group cut-off (AUC, 0.61 (95% CI, 0.51–0.70)),
while fetal Doppler (arterial or venous), birth-weight
MoM and gestational age were rejected from the model.
A similar model for improving the prediction of very
low STV and/or recurrent FHR decelerations (below DV
group safety-net criteria) failed (AUC, 0.51 (95% CI,
0.41–0.61)).
Adjusted ORs for 2-year survival without neurological
impairment of the STV regression line coefficient,
recurrent FHR decelerations, a low last STV (below CTG
group cut-off) or very low STV and/or recurrent FHR
decelerations (below DV group safety-net criteria) are
shown in Figure 3. ORs were adjusted for gestational
age and birth-weight MoM for each variable separately.
Group allocation (DV or CTG monitoring) had been
entered into this analysis but was rejected from the model.
None of these variables reached statistical significance.
We observed no association of a last STV below the
CTG group cut-off and/or recurrent FHR decelerations
with umbilical pH or Apgar score at birth, nor with the
incidence of severe neonatal morbidity or neurological
impairment at the age of 2 years. Because the last STV
value before delivery had no association with outcome, we
did not perform statistical analysis on earlier STV values.
DISCUSSION
In this post-hoc analysis of the TRUFFLE study data,
38% of women had a last STV below the CTG group
cut-off and 11% had a last STV below the DV group
cut-off, while recurrent FHR decelerations in the last
CTG were observed in 44% of women. Fifty percent of
women had a STV below the DV group cut-off and/or
recurrent FHR decelerations and surpassed the DV group
safety-net criteria. The DV safety-net criteria are therefore
an important part of the DV strategy, as defined in the
TRUFFLE protocol.
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After inclusion in the study, the daily risk of very
low STV and/or recurrent FHR decelerations (DV group
safety-net) was 5% (IQR, 4–7%). Within this group
of women with early FGR, this background risk of
surpassing the DV group safety-net criteria could not be
adjusted individually using longitudinal STV parameters,
fetal Doppler parameters (arterial or venous), nor any
other perinatal characteristics. The clinical implication
of this finding is that, if DV group safety-net criteria
are considered a valid and urgent indication for delivery,
then at least daily CTG recordings are needed. The study
data have insufficient power to address the question of
whether performing CTG more often than once daily
might improve detection.
Short- or long-term infant outcome was not associated
with longitudinal STV pattern, a last STV below the CTG
group cut-off or below the DV-group cut-off or with
recurrent FHR decelerations. In early preterm FGR, if
monitored properly and action is taken as specified in the
TRUFFLE protocol, it is not harmful to delay delivery
until CTG monitoring shows clear abnormalities. Because
two-thirds of this cohort had also been monitored for
DV-PI, this statement is probably only valid for women
with early FGR who were also monitored for DV-PI
and delivered when DV-PI was consistently abnormal.
This is supported by the observation of fetal death
approximately 12 h after a normal CTG in women with
DV-PI >95th percentile.
While we conclude that it is safe to delay intervention
until very low STV and/or recurrent FHR decelerations
occur, as long as CTG is recorded with sufficient
frequency and DV-PI is normal, we do not advocate
delaying delivery thereafter. Our study was not designed
to define the mortality risk after an abnormal CTG.
However, the occurrence of fetal death shortly after
refusal of intervention by two women, when low STV
and FHR decelerations were observed, supports the
need for delivery on this indication. These two women
were excluded from the present analysis because they
had insufficient STV data for longitudinal analysis.
The association of low STV variation and/or FHR
decelerations with fetal hypoxia and acidosis has been
observed4,8,9. Older studies support the generally accepted
opinion that delivery is indicated for low STV variation
and/or FHR decelerations to prevent fetal death10,11.
The observed differences in STV characteristics between
women who had corticosteroids 4–7 days before delivery
compared with women who had a longer interval or did
not receive corticosteroids were probably influenced by
other causes than the timing of steroid administration,
given the significant difference of the interval between
randomization and delivery and gestational age at delivery
between these groups.
One hundred and forty-nine (46%) of the 322 women
from the TRUFFLE study who delivered before 32weeks
and had complete 2-year follow-up had sufficient data
for the current analysis. They are deemed representative,
because no differences were observed in demographic
and perinatal data between the current selection and the
complete group of women who delivered before 32weeks
(data not shown). The only major difference of the current
selected cohort with the remaining women was in ante-
natal mortality; nearly all antenatal deaths (11/12; 92%)
were excluded because of insufficient data for longitudinal
analysis. Most of these had insufficient data because of
either refusal of intervention5 or inclusion to delivery
interval shorter than 4 days5. In one of these women,
more frequent CTG might have prevented fetal death.
Few studies have assessed longitudinal STV in women
with early FGR. One study demonstrated a gradually
decreasing STV of approximately 2.5 SD during the last
3 weeks before delivery2. If this cohort had the same
variation in STV as did ours, this must have been an
overall decrease of approximately 4 ms. This is far larger
than the slight decrease that was observed in our cohort
(0.84 ms/3 weeks). In our cohort, an individual decrease
> 3 ms/10 days was rare and seen mostly in cases with a
short interval to delivery. In our cohort, most decreases
in STV occurred only during the last 24 h before delivery.
Because the data in the study of Hecher et al.2 were
organized by gestational age, and deliveries occurred at
different gestational ages, data obtained shortly before
delivery could lower the average STV. Two longitudinal
studies in early FGR followed long-term FHR variation,
which has some relation to STV. One study observed
that variation was stable until a decrease on the last day
before delivery12. The other reported a slight decrease in
variation during the last 3 weeks of pregnancy, again with
the most significant decrease being on the last day13. These
data are in accordance with those of the present study.
There is no proof that CTG with STV calculation is
superior to visual analysis of CTG for fetal monitoring.
However, for research purposes, STV is superior to
visual analysis because it enables definition of strict
criteria for intervention, while visual analysis is subjective.
Implementation of an intervention protocol benefits from
well-defined criteria.
In conclusion, the TRUFFLE study showed that a
strategy of DV-PI monitoring with safety-net delivery
indication of very low STV and/or recurrent FHR
decelerations could increase infant survival without
neurological impairment at 2 years of age. This post-hoc
analysis demonstrates that, in early FGR, the daily risk of
abnormal CTG, as defined by the DV-PI group safety-net
criteria, is 5% and that prediction of this is not possible.
This supports the rationale for CTG monitoring more
often than daily in these high-risk fetuses. Low STV
and/or recurrent FHR decelerations were not associated
with adverse infant outcome and it appears safe to delay
intervention until such abnormalities occur, as long as
DV-PI is within the normal range.
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